Duchenne Muscular Dystrophy Treatment Market Size

Duchenne Muscular Dystrophy Treatment Market size was valued at USD 3.12 billion in 2023 and is expected to exceed USD 13.3 billion by 2036, expanding at over 11.8% CAGR during the forecast period i.e., between 2024-2036. In the year 2024, the industry size of duchenne muscular dystrophy treatment is assessed at USD 3.41 billion. Duchenne muscular dystrophy is an inherited muscular disorder, which results in extreme weakness in muscles. The growth of the market can be attributed to the increasing demand for treatment for Duchenne muscular dystrophy or DMD, along with rising research activities for the development of new treatment methods. Moreover, the growing prevalence of muscular disorders, backed by poor lifestyle and lack of physical activities, are estimated to boost the market growth. According to the data by the World Health Organization (WHO), 1.71 billion people suffer from musculoskeletal disorders. DMD is a type of myositis, which is why, it has no cure. The growing demand for myositis treatment, is anticipated to positively affect the market growth.

Furthermore, DMD is a rare genetic disorder, mostly prevalent amongst males. According to the National Organization of Rare Disorders (NORD), DMD affects approximately 1 in every 3,500 male births worldwide. The high share of male population, in the total global population is projected to promote the global market growth. In 2020, 50.415% of the global population, i.e., 3.907 billion people were male, as per the statistics by the World Bank.

In addition to this, the absence of any permanent treatment for this disorder, along with the growing investment in the R&D activities is estimated to boost the market growth.  According to the World Bank data, 2.204% of the global GDP was spent for R&D activities in 2018.